诱导免疫耐受的树突状细胞：急性肾损伤的有前途的细胞治疗方法。
Tolerogenic dendritic cells: promising cell therapy for acute kidney injury.
机构信息
Department of Physiology of Visceral Function and Body Fluid, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Physiology of Visceral Function and Body Fluid, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
出版信息
Kidney Int. 2023 Sep;104(3):420-422. doi: 10.1016/j.kint.2023.06.015.
There is still no established treatment for acute kidney injury (AKI), and the intervention of AKI remains limited to supportive treatments. Li et al. demonstrated the mechanism by which immune tolerance by dendritic cell ameliorates AKI in a mouse ischemia-reperfusion injury model. The phase I/II clinical trials of tolerogenic dendritic cell therapy have been conducted for kidney transplantation, so it is expected to have potential as a cell therapy for AKI in the future.
目前，急性肾损伤（AKI）仍缺乏有效的治疗方法，AKI 的干预措施仍仅限于支持性治疗。李等人在小鼠缺血再灌注损伤模型中证明了树突状细胞免疫耐受改善 AKI 的机制。用于肾移植的耐受树突状细胞治疗的 I/II 期临床试验已经开展，因此有望成为 AKI 的细胞治疗的一种潜在方法。
Zotero 插件